Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/04/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd has scheduled a Board meeting on 21 April 2026 to consider the appointment of Ms. Monam Kapoor (DIN: 09278005) as an Additional Director, designated as a Non-Executive Independent Director. The meeting will also discuss amending the company's Main Objects clause in the Memorandum of Association to diversify into multiple new sectors including drones and defence equipment, healthcare (hospitals, e-pharmacy, medical equipment), dairy products, AI/software/hardware, hospitality, and agro farming. A Postal Ballot will be proposed to seek shareholder approval for these changes.
The appointment of an independent director strengthens board governance. More significantly, the proposed diversification into drones, defence, healthcare, and AI signals a major strategic shift for the company, which could reshape its future earnings profile if shareholders approve the MOA amendment.